Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1967 1
1968 1
1970 1
1975 1
1976 1
1977 2
1978 2
1979 1
1982 1
1983 1
1984 1
1985 2
1986 4
1987 2
1988 3
1990 1
1996 1
1997 2
2001 2
2002 2
2003 2
2004 6
2005 4
2006 7
2007 7
2008 5
2009 9
2010 11
2011 3
2012 8
2013 7
2014 13
2015 6
2016 9
2017 11
2018 14
2019 11
2020 16
2021 18
2022 13
Text availability
Article attribute
Article type
Publication date

Search Results

200 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Practice Guideline to Improve Locomotor Function Following Chronic Stroke, Incomplete Spinal Cord Injury, and Brain Injury.
Hornby TG, Reisman DS, Ward IG, Scheets PL, Miller A, Haddad D, Fox EJ, Fritz NE, Hawkins K, Henderson CE, Hendron KL, Holleran CL, Lynskey JE, Walter A; and the Locomotor CPG Appraisal Team. Hornby TG, et al. Among authors: fox ej. J Neurol Phys Ther. 2020 Jan;44(1):49-100. doi: 10.1097/NPT.0000000000000303. J Neurol Phys Ther. 2020. PMID: 31834165 Review.
Single-synapse analyses of Alzheimer's disease implicate pathologic tau, DJ1, CD47, and ApoE.
Phongpreecha T, Gajera CR, Liu CC, Vijayaragavan K, Chang AL, Becker M, Fallahzadeh R, Fernandez R, Postupna N, Sherfield E, Tebaykin D, Latimer C, Shively CA, Register TC, Craft S, Montine KS, Fox EJ, Poston KL, Keene CD, Angelo M, Bendall SC, Aghaeepour N, Montine TJ. Phongpreecha T, et al. Among authors: fox ej. Sci Adv. 2021 Dec 17;7(51):eabk0473. doi: 10.1126/sciadv.abk0473. Epub 2021 Dec 15. Sci Adv. 2021. PMID: 34910503 Free PMC article.
Detection of ultra-rare mutations by next-generation sequencing.
Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Schmitt MW, et al. Among authors: fox ej. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14508-13. doi: 10.1073/pnas.1208715109. Epub 2012 Aug 1. Proc Natl Acad Sci U S A. 2012. PMID: 22853953 Free PMC article.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Among authors: fox ej. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M, Munger KL, Martínez-Lapiscina EH, Barro C, Edan G, Freedman MS, Hartung HP, Montalbán X, Foley FW, Penner IK, Hemmer B, Fox EJ, Schippling S, Wicklein EM, Kappos L, Kuhle J, Ascherio A; BENEFIT Study Group. Cortese M, et al. Among authors: fox ej. Neurology. 2020 May 5;94(18):e1950-e1960. doi: 10.1212/WNL.0000000000009371. Epub 2020 Apr 16. Neurology. 2020. PMID: 32300060 Free PMC article. Clinical Trial.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Cohen JA, et al. Among authors: fox ej. Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122652 Clinical Trial.
200 results